<DOC>
	<DOCNO>NCT01589159</DOCNO>
	<brief_summary>This single-center , open-lable , non-comparative , prospective , phase Ⅱ efficacy safety study . Eligible patient enrol single group . The investigator propose determine efficacy safety low-dose metronomic chemotherapy Etoposide/Capecitabine Patients Metastatic Breast Cancer Previously Treated Anthracyclines and/or Taxanes .</brief_summary>
	<brief_title>A Phase Ⅱ Study All-Oral Combination Low-dose Etoposide/Capecitabine Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>female patient 18 65 year old patient metastatic breast cancer previousely treat A/T able willing give consent participate study pregnant lactating female tumor history instable complication ( e.g. , myocardial infarction within 6 month , arrhythmia , unstable diabetes , hypercalcemia ) uncontrolled infection concurrent disease condition would make patient inappropriate study participation resist participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>